Plus Therapeutics Reports Clinical Progress and Financial Updates
Plus Therapeutics, now operating as Cerenome, announced the completion of enrollment in its Phase 2 glioblastoma trial and provided interim data for its REYOBIQ™ leptomeningeal metastases program.